Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Trial Profile

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2019

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2015 Efficacy at 24 months, results presented at the 1st Congress of the European Academy of Neurology.
    • 30 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 03 Jun 2014 Interim results at 12 months presented at the 2014 Congress of European Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top